ПЕРСПЕКТИВА ПРИМЕНЕНИЯ КОНЦЕПЦИИ МОРФОФУНКЦИОНАЛЬНОЙ СИСТЕМЫ «КОНДУИТ – АРТЕРИЯ» ПРИ ВЗАИМОДЕЙСТВИИ КОРОНАРНОЙ АРТЕРИИ СО СТЕНТОМ/БАЛЛОНОМ

Основные положения

• В аналитическом обзоре предлагается обратиться к предложенной ранее концепции морфофункциональной системы «кондуит – артерия», используемой при «открытых» кардиохирургических вмешательствах.
• На основе указанной концепции приводится ее аналог в виде моделирования морфофункциональной системы «стент/баллон – артерия» для эндоваскулярного лечения коронарного атеросклероза.

Резюме

В обзорной статье приводится потенциальное моделирование взаимодействия стента/баллона с коронарной артерией по аналогии и на основе ранее предложенной концепции морфофункциональной системы «кондуит – артерия», которая обосновывает преимущества и недостатки различных вариантов коронарного шунтирования и имеет важное прикладное значение при выборе трансплантата. Указанное взаимодействие при проведении эндоваскулярного лечения ишемической болезни сердца играет важную роль в разработке нового поколения устройств, а также в управлении различными факторами, участвующими в профилактике дисфункции стента и прогрессирования коронарного атеросклероза.

1. Фролов А.В. Морфофункциональная система «кондуит-артерия». Комплексные проблемы сердечно-сосудистых заболеваний. 2019:8 (1): 112-122. doi: 10.17802/2306-1278-2019-8-1-112-122

2. Ahadi F., Azadi M., Biglari M., Bodaghi M., Khaleghian A. Evaluation of coronary stents: A review of types, materials, processing techniques, design, and problems. Heliyon. 2023:9(2):e13575. doi: 10.1016/j.heliyon.2023.e13575

3. Piccolo R., Bonaa K.H., Efthimiou O., Varenne O., Baldo A., Urban P., Kaiser C., Remkes W., Räber L., de Belder A., van ’t Hof A.W.J., Stankovic G., Lemos P.A., Wilsgaard T., Reifart J., Rodriguez A.E., Ribeiro E.E., Serruys P.W.J.C., Abizaid A., Sabaté M., Byrne R.A., de la Torre Hernandez J.M., Wijns W., Jüni P., Windecker S., Valgimigli M. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet. 2019:393: 2503-10. doi: 10.1016/S0140-6736(19)30474-X

4. Jackson-Smith E., Zioupos S., Banerjee P. Bioresorbable vascular scaffolds versus conventional drug-eluting stents across time: a meta-analysis of randomised controlled trials. Open Heart. 2022:9:e002107. doi:10.1136/openhrt-2022-002107

5. Lawton J.S., Tamis-Holland J.E., Bangalore S., Bates E.R., Beckie T.M., Bischoff J.M., Bittl J.A., Cohen M.G., DiMaio J.M., Don C.W., Fremes S.E., Gaudino M.F., Goldberger Z.D., Grant M.C., Jaswal J.B., Kurlansky P.A., Mehran R., Metkus T.S. Jr., Nnacheta L.C., Rao S.V., Sellke F.W., Sharma G., Yong C.M., Zwischenberger B.A. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022:18;145(3):e4-e17. doi: 10.1161/CIR.0000000000001039

6. Pelliccia F., Zimarino M., Niccoli G., Morrone D., De Luca G., Miraldi F., De Caterina R. In-stent restenosis after percutaneous coronary intervention: emerging knowledge on biological pathways. Eur Heart J Open. 2023 Aug 24;3(5):oead083. doi: 10.1093/ehjopen/oead083

7. Paramasivam G., Devasia T., Ubaid S., Shetty A., Nayak K., Pai U., Rao M.S. In-stent restenosis of drug-eluting stents: clinical presentation and outcomes in a real-world scenario. The Egyptian Heart Journal. 2019:71:28. doi: 10.1186/s43044-019-0025-z

8. Condello F., Spaccarotella C., Sorrentino S., Indolfi C., Stefanini G.G., Polimeni A. Stent Thrombosis and Restenosis with Contemporary Drug-Eluting Stents: Predictors and Current Evidence. J. Clin. Med. 2023:12:1238. doi: 10.3390/jcm12031238

9. Chacko L., Howard J.P., Rajkumar C., Nowbar A.N., Kane C., Mahdi D., Foley M., Shun-Shin M., Cole G., Sen S., Al-Lamee R., Francis D.P., Ahmad Y. Effects of Percutaneous Coronary Intervention on Death and Myocardial Infarction Stratified by Stable and Unstable Coronary Artery Disease A Meta-Analysis of Randomized Controlled Trials. Circ Cardiovasc Qual Outcomes. 2020;13:e006363. doi: 10.1161/CIRCOUTCOMES.119.006363

10. Saito Y., Oyama K., Tsujita K., Yasuda S., Kobayashi Y. Treatment strategies of acute myocardial infarction: updates on revascularization, pharmacological therapy, and beyond. Journal of Cardiology. 2023:168-178. doi: 10.1016/j.jjcc.2022.07.003

11. Piccolo R., Bonaa K.H., Efthimiou O., Varenne O., Urban P., Kaiser C., Räber L., de Belder A., Remkes W., van’t Hof A.W.J., Stankovic G., Lemos P.A., Wilsgaard T., Reifart J., Rodriguez A.E., Ribeiro E.E., Serruys P.W.J.C., Abizaid A., Sabaté M., Byrne R.A., de la Torre Hernandez J.M., Wijns W., Esposito G., Jüni P., Windecker S., Valgimigli M. Drug-Eluting or Bare-Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization. J Am Heart Assoc. 2021:10:e018828. doi: 10.1161/JAHA.120.018828

12. Yamada K., Mizutani Y., Nakamura H., Ukaji T., Sato H., Koshikawa Y., Hori Y., Itabashi Y., Nakahara S., Ishikawa T., Kobayashi S., Taguchi I. Reperfusion Injury after Acute Myocardial Infarction. Dokkyo Medical Journal 2022:1(4): 274-284. doi: 10.51040/dkmj.2022-028

13. Bytyçi I., Morina D., Bytyqi S., Bajraktari G., Henein M.Y. Percutaneous Coronary Intervention Is Not Superior to Optimal Medical Therapy in Chronic Coronary Syndrome: A Meta-Analysis. J. Clin. Med. 2023:12:1395. doi: 10.3390/jcm12041395

14. Madhavan M.V., Kirtane A.J., Redfors B., Généreux P., Ben-Yehuda O., Palmerini T., Benedetto U., Biondi-Zoccai G., Smits P.C., von Birgelen C., Mehran R., McAndrew T., Serruys P.W., Leon M.B., Pocock S.J., Stone G.W. Stent-Related Adverse Events > 1 Year After Percutaneous Coronary Intervention. JACC. 2020:75(6):590-604. doi: 10.1016/j.jacc.2019.11.058

15. Cassese S., Byrne R.A., Tada T., Pinieck S., Joner M., Ibrahim T., King L.A., Fusaro M., Laugwitz K.-L., Kastrati A. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart 2014;100:153-159. doi: 10.1136/heartjnl-2013-304933

16. Wan Y-D., Wang D-Y., Deng W-Q., Lai S-J., Wang X. Bioresorbable scaffolds vs. drug-eluting stents on short- and mid-term target lesion outcomes in patients after PCI: A systematic review and meta-analysis. Front Cardiovasc Med. 2022 9:949494. doi: 10.3389/fcvm.2022.949494

17. Klein L.W., Nathan S., Maehara A., Messenger J., Mintz G.S., Ali Z.A., Rymer J., Sandoval Y., Al-Azizi K., Mehran R., Rao S.V., Lotfi A. SCAI Expert Consensus Statement on Management of In-Stent Restenosis and Stent Thrombosis. Journal of the Society for Cardiovascular Angiography & Interventions 2023:100971. doi: 10.1016/j.jscai.2023.100971

18. Clare J., Ganly J., Bursill C.A., Sumer H., Kingshott P., de Haan J.B. The Mechanisms of Restenosis and Relevance to Next Generation Stent Design. Biomolecules. 2022:12:430. doi: 10.3390/biom12030430

19. Mehran R., Dangas G., Abizaid A.S., Mintz G.S., Lansky A.J., Satler L.F., Pichard A.D., Kent K.M., Stone G.W., Leon M.B. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999:100(18):1872-1878. doi: 10.1161/01.cir.100.18.1872

20. Shlofmitz E., Iantorno M., Waksman R. Restenosis of drug-eluting stents: a new classification system based on disease mechanism to guide treatment and stateof-the-art review. Circ Cardiovasc Interv. 2019:12(8): e007023. doi: 10.1161/CIRCINTERVENTIONS.118.007023

21. Kang S.J., Mintz G.S., Park D.W., Lee S.W., Kim Y.H., Lee C.W., Han K.H., Kim J.J., Park S.W., Park S.J. Tissue characterization of in-stent neointima using intravascular ultrasound radiofrequency data analysis. Am J Cardiol. 2010:106(11):1561-1565. doi: 10.1016/j.amjcard.2010.07.031

22. Gonzalo N., Serruys P.W., Okamura T., van Beusekom H.M., Garcia-Garcia H.M., van Soest G., van der Giessen W., Regar E. Optical coherence tomography patterns of stent restenosis. Am Heart J. 2009:158(2):284-293. doi: 10.1016/j.ahj.2009.06.004

23. Ali Z.A., Roleder T., Narula J., Mohanty B.D., Baber U., Kovacic J.C., Mintz G.S., Otsuka F., Pan S., Virmani R., Sharma S.K., Moreno P., Kini A.S. Increased thin-cap neoatheroma and periprocedural myocardial infarction in drug-eluting stent restenosis: multimodality intravascular imaging of drug-eluting and bare-metal stents. Circ Cardiovasc Interv. 2013:6(5):507-517. doi: 10.1161/CIRCINTERVENTIONS.112.000248

24. Her A.-Y., Shin E.-S. Current Management of In-Stent Restenosis. Korean Circ J. 2018:48(5):337-349. doi: 10.4070/kcj.2018.0103

25. Pleva L., Kukla P., Hlinomaz O. Treatment of coronary in-stent restenosis: a systematic review. Journal of Geriatric Cardiology 2018:15:173-184. doi: 10.11909/j.issn.1671-5411.2018.02.007

26. Bajeu I.-T., Niculescu A.-G., Scafa-Udris te A., Andronescu E. Intrastent Restenosis: A Comprehensive Review. Int J Mol Sci 2024:25:1715. doi: 10.3390/ijms25031715

27. Ashrafian H., Darzi A., Athanasiou T. Auto-bionics – a new paradigm in Regenerative Medicine and Surgery. Regen Med. 2010:5(2):279-288. doi: 10.2217/rme.10.2

28. Фролов А.В. Морфофункциональная система кондуит-артерия: клинико-патофизиологическая концепция как основа эффективности аутоартериального коронарного шунтирования: дисс. … док. мед. наук. Кемерово, 2023. 388 с.

29. Gori T. Vascular Wall Reactions to Coronary Stents – Clinical Implications for Stent Failure. Life. 2021:11:63. doi: 10.3390/life11010063

30. Hu W., Jiang J. Hypersensitivity and in-stent restenosis in coronary stent materials. Front. Bioeng Biotechnol. 2022:10:1003322. doi: 10.3389/fbioe.2022.1003322

31. Brami P., Fischer Q., Pham V., Seret G., Varenne O., Picard F. Evolution of Coronary Stent Platforms: A Brief Overview of Currently Used Drug-Eluting Stents. J Clin Med. 2023:12:6711. doi: 10.3390/jcm12216711

32. Nicolas J., Pivato C.A., Chiarito M., Beerkens F., Cao D., Mehran R. Evolution of drug-eluting coronary stents: a backand-forth journey from the bench to bedside. Cardiovascular Research. 2023:119:631-646. doi: 10.1093/cvr/cvac105

33. Chioncel V., Andrei C.L., Brezeanu R., Sinescu C., Avram A., Tatu A.L. Some Perspectives on Hypersensitivity to Coronary Stents. International Journal of General Medicine 2021:14:4327-4336. doi: 10.2147/IJGM.S326679

34. Cook S., Ladich E., Nakazawa G., Eshtehardi P., Neidhart M., Vogel R., Togni M., Wenaweser P., Billinger M., Seiler C., Gay S., Meier B., Pichler W.J., Jüni P., Virmani R., Windecker S. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation. 2009:120(5):391-399. doi:10.1161/CIRCULATIONAHA.109.

35. Otsuka F., Yahagi K., Ladich E., Kutys R., Alexander R., Fowler D., Virmani R., Joner M. Hypersensitivity reaction in the US food and drug administration-approved second-generation drug-eluting stents: Histopathological assessment with ex vivo optical coherence tomography. Circulation. 2015:131(3):322-324. doi: 10.1161/CIRCULATIONAHA.114.012658

36. Strohbach A., Busch R. Polymers for Cardiovascular Stent Coatings. International Journal of Polymer Science. 2015:782653. doi: 10.1155/2015/782653

37. Kozlik M., Harpula J., Chuchra P.J., Nowak M., Wojakowski W., Gasior P. Drug-Eluting Stents: Technical and Clinical Progress. Biomimetics. 2023:8:72. doi: 10.3390/biomimetics8010072

38. Marei I., Ahmetaj-Shala B., Triggle C.R. Biofunctionalization of cardiovascular stents to induce endothelialization: Implications for instent thrombosis in diabetes. Front Pharmacol. 2022:13:982185. doi: 10.3389/fphar.2022.982185

39. Daoud F.C., Catargi B., Karjalainen P.P., Gerbaud E. Five-Year Efficacy and Safety of TiNO-Coated Stents Versus Drug-Eluting Stents in Acute Coronary Syndrome: A Meta-Analysis. J Clin Med. 2023:6;12(21):6952. doi: 10.3390/jcm12216952

40. Saqib M., Kuzmin O.S., Kraskiewicz H., Wasyluk L., Cuniberti G., Ficai A.A., Pichugin V.F., Opitz J., Beshchasna N. Evaluation of in Vitro Corrosion Behavior of Titanium Oxynitride Coated Stainless Steel Stents. IEEE Access, 2021:9:59766-59782. doi: 10.1109/ACCESS.2021.3072597

41. Lee D.-H., de la Torre Hernandez J.M. The Newest Generation of Drug-eluting Stents and Beyond. European Cardiology Review 2018:13(1):54-9. doi: 10.15420/ecr.2018:8:2

42. Shishkova D., Markova V., Sinitsky M., Tsepokina A., Frolov A., Zagorodnikov N., Bogdanov L., Kutikhin A. Co-Culture of Primary Human Coronary Artery and Internal Thoracic Artery Endothelial Cells Results in Mutually Beneficial Paracrine Interactions. Int J Mol Sci. 2020:21(21):8032. doi: 10.3390/ijms21218032

43. Spadaccio C., Antoniades C., Nenna A., Chung C., Will R., Chello M., Gaudino M.F.L. Preventing treatment failures in coronary artery disease: what can we learn from the biology of in-stent restenosis, vein graft failure, and internal thoracic arteries? Cardiovasc Res. 2020:116 (3):505-519. doi: 10.1093/cvr/cvz214

44. Peng X., Qu W., Jia Y., Wang Y., Yu B., Tian J. Bioresorbable Scaffolds: Contemporary Status and Future Directions. Front Cardiovasc Med. 2020:30(7):589571. doi: 10.3389/fcvm.2020.589571

45. Forrestal B., Case B.C., Yerasi C., Musallam A., Chezar-Azerrad C., Waksman R. Bioresorbable Scaffolds: Current Technology and Future Perspectives. Rambam Maimonides Med J. 2020:29:11(2):e0016. doi: 10.5041/RMMJ.10402

46. Stone G.W., Kereiakes D.J., Gori T., Metzger D.C., Stein B., Erickson M., Torzewski J., Kabour A., Piegari G., Cavendish J., Bertolet B., Stockelman K.A., West N.E.J., Ben-Yehuda O., Choi J.W., Marx S.O., Spertus J.A., Ellis S.G.; ABSORB IV Investigators. 5-Year Outcomes After Bioresorbable Coronary Scaffolds Implanted With Improved Technique. J Am Coll Cardiol. 2023:18:82(3):183-195. doi: 10.1016/j.jacc.2023.05.003

47. Shishatskaya E.I., Menzyanova N.G., Shumilova A.A. The effect of the chemical composition and structure of polymer films made from resorbable polyhydroxyalkanoates on blood cell response. Int J Biol Macromol. 2019:1(141):765-775. doi: 10.1016/j.ijbiomac.2019.09.015

48. Barungi S., Hernández-Camarero P., Moreno-Terribas G., Villalba-Montoro R., Marchal J.A., López-Ruiz E., Perán M. Clinical implications of inflammation in atheroma formation and novel therapies in cardiovascular diseases. Front Cell Dev Biol. 2023:16(11):1148768. doi: 10.3389/fcell.2023.1148768

49. Aziz K.S., Saxton G.M., inventors; Atherolysis Medical, Inc., assignee. Atherosclerotic plaque dissolution composition. United States patent US 13/087,520. 2011 Apr 15

50. Аprotosoaie A.C., Costache A.-D., Costache I.-I. Therapeutic Strategies and Chemoprevention of Atherosclerosis: What Do We Know and Where Do We Go? Pharmaceutics. 2022:14:722. doi: 10.3390/ pharmaceutics14040722

51. Wang S., Chen C.Y., Rzasa J.R., Tsao C.Y., Li J., Van Arsdale E., Kim E., Zakaria F.R., Payne G.F., Bentley W.E. Redox-enabled electronic interrogation and feedback control of hierarchical and networked biological systems. Nat Commun. 2023:14(1):8514. doi: 10.1038/s41467-023-44223-w

52. Mazzotti G., Hartmann D., Booth M.J. Precise, Orthogonal Remote-Control of Cell-Free Systems Using Photocaged Nucleic Acids. J Am Chem Soc. 2023:145(17):9481-9487. doi: 10.1021/jacs.3c01238

53. Mundell J.W., Brier M.I., Orloff E., Stanley S.A., Dordick J.S. Alternating magnetic fields drive stimulation of gene expression via generation of reactive oxygen species. iScience. 2024:27(3):109186. doi: 10.1016/j.isci.2024.109186

54. Mosabbir A.A., Truong K. Genetically Encoded Circuit for Remote Regulation of Cell Migration by Magnetic Fields. ACS Synth Biol. 2018:7(2):718-726. doi: 10.1021/acssynbio.7b00415

55. Wang L., Li X., Li T., Liu L., Wang H., Wang C. Novel application of drug-coated balloons in coronary heart disease: A narrative review. Front Cardiovasc Med. 2023:10:1055274. doi: 10.3389/fcvm.2023.1055274

56. Rivero-Santana B., Jurado-Roman A., Galeote G., Jimenez-Valero S., Gonzalvez A., Tebar D., Moreno R. Drug-Eluting Balloons in Calcified Coronary Lesions: A Meta-Analysis of Clinical and Angiographic Outcomes. J Clin Med. 2024:13(10):2779. doi: 10.3390/jcm13102779